DP8 Stock Chart & Stats
€2.20
-€0.08(-3.51%)
At close: 4:00 PM EDT
€2.20
-€0.08(-3.51%)
Day’s Range― - ―
52-Week Range€1.81 - €8.95
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€33.05M
Enterprise Value€6.82
Total Cash (Recent Filing)€24.94M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Nov 16, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.38Price Target Upside508.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.81
Revenue Forecast (FY)€228.11K
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway SupportThe ILAP designation provides structured access to UK regulators, health technology bodies and the NHS. This may improve development coordination, regulatory positioning and eventual patient-access planning for a high-unmet-need indication.
Improved Phase 3 StrategyExposure-response findings and patient-selection insights give CervoMed a more defined development strategy after earlier mixed results. Better dose and biomarker alignment could reduce execution risk in the next pivotal study.
Strengthened Intellectual PropertyLong-duration patent protection can support future commercial exclusivity if clinical efficacy is confirmed. It strengthens the strategic value of neflamapimod and may improve the company’s position in partnerships or licensing discussions.
Bears Say
Minimal Commercial RevenueCervoMed has not reached commercial scale and generates little product revenue, leaving its economics dependent on successful clinical development. Large ongoing losses indicate that profitability remains distant and highly contingent on approval.
Heavy Cash Burn And Funding DependencePersistent operating outflows require continued access to equity, partnerships or other financing before meaningful revenue emerges. This limits financial flexibility and creates dilution or execution risk as the pipeline advances toward Phase 3.
Clinical Efficacy UncertaintyAlthough later analyses support a revised dose and target population, the prior Phase 2b outcome leaves efficacy unproven. A future pivotal trial could still fail, materially weakening the pipeline and the company’s long-term prospects.
CervoMed News
DP8 FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was €1.81 and its highest was €8.95 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is €33.05M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Nov 16, 2026 which is in 71 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Aug 10, 2026. The company reported -€0.548 earnings per share for the quarter, beating the consensus estimate of -€0.682 by €0.134.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.42.
How many shares outstanding does CervoMed have?
CervoMed has 15,119,096 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -€0.548 in its last earnings report, beating expectations of -€0.682. Following the earnings report the stock price went up 4.464%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in DE:DP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.38 (508.10% Upside)
€13.38 (508.10% Upside)
Blogger Sentiment
Bullish
DE:DP8 Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth €2.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
DP8 Stock 12 Month Forecast
Average Price Target
€13.38
▲(508.10% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―